After traumatic spinal cord injury, grossly injured blood vessels leak blood and fluid into the parenchyma, leading to a large cystic cavity. Fibroblast growth factor-2 (FGF2) can reduce immediate vasoconstriction of vessels in the tissue surrounding the primary injury and promote angiogenesis. A localized delivery system would both achieve restricted delivery of FGF2 to the spinal cord and limit possible systemic effects such as mitogenesis. To enhance the endogenous angiogenic response after spinal cord injury, FGF2 was encapsulated in poly(lactide-co-glycolide) (PLGA) nanoparticles which were embedded in a biopolymer blend of hyaluronan and methylcellulose (HAMC) and then injected into the intrathecal space. Treatment began immediately after a 26 g clip compression spinal cord injury in rats and consisted of intrathecal delivery of FGF2 from the HAMC/PLGA/FGF2 composite. Control animals received intrathecal HAMC loaded with blank nanoparticles, intrathecal HAMC alone or intrathecal artificial cerebrospinal fluid alone. Sustained and localized delivery of FGF2 from composite HAMC/PLGA/FGF2 achieved higher blood vessel density in the dorsal horns 28 days post-injury, due to either greater angiogenesis near the epicenter of the injury or vasoprotection acutely after spinal cord injury. Importantly, delivery of FGF2 from composite HAMC/PLGA/FGF2 did not produce proliferative lesions that had been previously reported for FGF2 delivered locally using a minipump/catheter. These results suggest that localized and sustained delivery with composite HAMC/PLGA/FGF2 is an excellent system to deliver biomolecules directly to the spinal cord, thereby circumventing the blood spinal cord barrier and avoiding systemic side effects.

Keywords:
Growth factors, Traumatic spinal cord injury, Therapeutic approaches, Central nervous system injury
1.
Basso, D.M., M.S. Beattie, et al. (1995) A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12: 1–21.
2.
Baumann, M.D., C.E. Kang, et al. (2009) An injectable drug delivery platform for sustained combination therapy. J Control Release 138: 205–213.
3.
Baumann, M.D., C.E. Kang, et al. (2010) Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury. Biomaterials 31: 7631–7639.
4.
Bogousslavsky, J., S.J. Victor, et al. (2002) Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 14: 239–251.
5.
Cuevas, P., F. Carceller, et al. (1991) Hypotensive activity of fibroblast growth factor. Science 254: 1208–1210.
6.
Fehlings, M.G. (2001) Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine 26(suppl 24): S56–S57.
7.
Gupta, D., C.H. Tator, et al. (2006) Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 27: 2370–2379.
8.
Hawryluk, G.W., J. Rowland, et al. (2008) Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 25: E14.
9.
Jones, L.L. and M.H. Tuszynski (2001) Chronic intrathecal infusions after spinal cord injury cause scarring and compression. Microsc Res Tech 54: 317–324.
10.
Kang, C.E., R. Clarkson, et al. (2010a) Spinal cord blood flow and blood vessel permeability measured by dynamic computed tomography imaging in rats after localized delivery of fibroblast growth factor. J Neurotrauma 27: 2041–2053.
11.
Kang, C.E., P.C. Poon, et al. (2009) A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair. Tissue Eng Part A 15: 595–604.
12.
Kang, C.E., C.H. Tator, et al. (2010b) Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system. J Control Release 144: 25–31.
13.
Koyanagi, I., C.H. Tator, et al. (1993a) Three-dimensional analysis of the vascular system in the rat spinal cord with scanning electron microscopy of vascular corrosion casts. 1. Normal spinal cord. Neurosurgery 33: 277–274.
14.
Koyanagi, I., C.H. Tator, et al. (1993b) Three-dimensional analysis of the vascular system in the rat spinal cord with scanning electron microscopy of vascular corrosion casts. 2. Acute spinal cord injury. Neurosurgery 33: 285–292.
15.
Lee, T.T., B.A. Green, et al. (1999) Neuroprotective effects of basic fibroblast growth factor following spinal cord contusion injury in the rat. J Neurotrauma 16: 347–356.
16.
Loy, D.N., C.H. Crawford, et al. (2002) Temporal progression of angiogenesis and basal lamina deposition after contusive spinal cord injury in the adult rat. J Comp Neurol 445: 308–324.
17.
Montesano, R., J.D. Vassalli, et al. (1986) Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 83: 7297–7301.
18.
Nozaki, K., S.P. Finklestein, et al. (1993) Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats. J Cereb Blood Flow Metab 13: 221–228.
19.
Parr, A.M., C.H. Tator (2007) Intrathecal epidermal growth factor and fibroblast growth factor-2 exacerbate meningeal proliferative lesions associated with intrathecal catheters. Neurosurgery 60: 926–933.
20.
Popovich, P.G., P.J. Horner, et al. (1996) A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp Neurol 142: 258–275.
21.
Rabchevsky, A.G., I. Fugaccia, et al. (1999) Basic fibroblast growth factor (bFGF) enhances tissue sparing and functional recovery following moderate spinal cord injury. J Neurotrauma 16: 817–830.
22.
Rabchevsky, A.G., I. Fugaccia, et al. (2000) Basic fibroblast growth factor (bFGF) enhances functional recovery following severe spinal cord injury to the rat. Exp Neurol 164: 280–291.
23.
Relf, M., S. LeJeune, et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963–969.
24.
Reuss, B., R. Dono, et al. (2003) Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. J Neurosci 23: 6404–6412.
25.
Rivlin, A.S. and C.H. Tator (1978) Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 10: 38–43.
26.
Shing, Y., J. Folkman, et al. (1985) Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 29: 275–287.
27.
Tator, C.H. (2006) Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 59: 957–987.
28.
Wang, Y., Y. Lapitsky, et al. (2009) Accelerated release of a sparingly soluble drug from an injectable hyaluronan-methylcellulose hydrogel. J Control Release 140: 218–223.
29.
Ziche, M., L. Morbidelli (2000) Nitric oxide and angiogenesis. J Neurooncol 50: 139–148.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.